Result Number | Material Type | Add to My Shelf Action | Record Details and Options |
---|---|---|---|
1 |
Material Type: Article
|
Estrogen and Progesterone Receptor Testing in Breast Cancer: ASCO/CAP Guideline UpdateJournal of clinical oncology, 2020-04, Vol.38 (12), p.1346-1366 [Peer Reviewed Journal]ISSN: 0732-183X ;EISSN: 1527-7755 ;DOI: 10.1200/jco.19.02309 ;PMID: 31928404Full text available |
|
2 |
Material Type: Article
|
Gene Expression Profiling in Breast Cancer: Understanding the Molecular Basis of Histologic Grade To Improve PrognosisJNCI : Journal of the National Cancer Institute, 2006-02, Vol.98 (4), p.262-272 [Peer Reviewed Journal]2006 INIST-CNRS ;Copyright Oxford University Press(England) Feb 15, 2006 ;ISSN: 0027-8874 ;ISSN: 1460-2105 ;EISSN: 1460-2105 ;DOI: 10.1093/jnci/djj052 ;PMID: 16478745 ;CODEN: JNCIEQFull text available |
|
3 |
Material Type: Article
|
Trastuzumab plus adjuvant chemotherapy for human epidermal growth factor receptor 2-positive breast cancer: planned joint analysis of overall survival from NSABP B-31 and NCCTG N9831Journal of clinical oncology, 2014-11, Vol.32 (33), p.3744-3752 [Peer Reviewed Journal]2014 by American Society of Clinical Oncology. ;2014 by American Society of Clinical Oncology 2014 ;ISSN: 0732-183X ;EISSN: 1527-7755 ;DOI: 10.1200/jco.2014.55.5730 ;PMID: 25332249Full text available |
|
4 |
Material Type: Article
|
The Intestinal Microbiome and Estrogen Receptor-Positive Female Breast CancerJNCI : Journal of the National Cancer Institute, 2016-08, Vol.108 (8) [Peer Reviewed Journal]The Author 2016. Published by Oxford University Press. All rights reserved. For Permissions, please e-mail: journals.permissions@oup.com. ;The Author 2016. Published by Oxford University Press. All rights reserved. For Permissions, please e-mail: journals.permissions@oup.com. 2016 ;ISSN: 1460-2105 ;ISSN: 0027-8874 ;EISSN: 1460-2105 ;DOI: 10.1093/jnci/djw029 ;PMID: 27107051Full text available |
|
5 |
Material Type: Article
|
Molecular phenotypes of DCIS predict overall and invasive recurrenceAnnals of oncology, 2015-05, Vol.26 (5), p.1019-1025 [Peer Reviewed Journal]2015 European Society for Medical Oncology ;The Author 2015. Published by Oxford University Press on behalf of the European Society for Medical Oncology. All rights reserved. For permissions, please email: journals.permissions@oup.com. ;ISSN: 0923-7534 ;EISSN: 1569-8041 ;DOI: 10.1093/annonc/mdv062 ;PMID: 25678586Full text available |
|
6 |
Material Type: Article
|
Different signatures of miR-16, miR-30b and miR-93 in exosomes from breast cancer and DCIS patientsScientific reports, 2018-08, Vol.8 (1), p.12974-10, Article 12974 [Peer Reviewed Journal]2018. This work is published under http://creativecommons.org/licenses/by/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License. ;The Author(s) 2018 ;ISSN: 2045-2322 ;EISSN: 2045-2322 ;DOI: 10.1038/s41598-018-31108-y ;PMID: 30154547Full text available |
|
7 |
Material Type: Article
|
Relevance of Tumor-Infiltrating Immune Cell Composition and Functionality for Disease Outcome in Breast CancerJNCI : Journal of the National Cancer Institute, 2017-01, Vol.109 (1), p.djw192 [Peer Reviewed Journal]The Author 2016. Published by Oxford University Press. All rights reserved. For Permissions, please email: journals.permissions@oup.com. ;The Author 2016. Published by Oxford University Press. All rights reserved. For Permissions, please email: journals.permissions@oup.com 2016 ;ISSN: 0027-8874 ;EISSN: 1460-2105 ;DOI: 10.1093/jnci/djw192 ;PMID: 27737921Full text available |
|
8 |
Material Type: Article
|
Acetate Dependence of TumorsCell, 2014-12, Vol.159 (7), p.1591-1602 [Peer Reviewed Journal]2014 Elsevier Inc. ;Copyright © 2014 Elsevier Inc. All rights reserved. ;2014 Elsevier Inc. All rights reserved. 2014 ;ISSN: 0092-8674 ;EISSN: 1097-4172 ;DOI: 10.1016/j.cell.2014.11.020 ;PMID: 25525877Full text available |
|
9 |
Material Type: Article
|
Trastuzumab emtansine versus treatment of physician's choice for pretreated HER2-positive advanced breast cancer (TH3RESA): a randomised, open-label, phase 3 trialThe lancet oncology, 2014-06, Vol.15 (7), p.689-699 [Peer Reviewed Journal]Elsevier Ltd ;2014 Elsevier Ltd ;Copyright © 2014 Elsevier Ltd. All rights reserved. ;Copyright Elsevier Limited Jun 2014 ;ISSN: 1470-2045 ;EISSN: 1474-5488 ;DOI: 10.1016/S1470-2045(14)70178-0 ;PMID: 24793816 ;CODEN: LANCAOFull text available |
|
10 |
Material Type: Article
|
Trastuzumab Emtansine With or Without Pertuzumab Versus Trastuzumab Plus Taxane for Human Epidermal Growth Factor Receptor 2-Positive, Advanced Breast Cancer: Primary Results From the Phase III MARIANNE StudyJournal of clinical oncology, 2017-01, Vol.35 (2), p.141-148 [Peer Reviewed Journal]2016 by American Society of Clinical Oncology 2016 American Society of Clinical Oncology ;ISSN: 0732-183X ;EISSN: 1527-7755 ;DOI: 10.1200/JCO.2016.67.4887 ;PMID: 28056202Full text available |
|
11 |
Material Type: Article
|
Long-Term Prognostic Risk After Neoadjuvant Chemotherapy Associated With Residual Cancer Burden and Breast Cancer SubtypeJournal of clinical oncology, 2017-04, Vol.35 (10), p.1049-1060 [Peer Reviewed Journal]2017 by American Society of Clinical Oncology 2017 American Society of Clinical Oncology ;ISSN: 0732-183X ;EISSN: 1527-7755 ;DOI: 10.1200/JCO.2015.63.1010 ;PMID: 28135148Full text available |
|
12 |
Material Type: Article
|
Neoadjuvant carboplatin in patients with triple-negative and HER2-positive early breast cancer (GeparSixto; GBG 66): a randomised phase 2 trialThe lancet oncology, 2014-06, Vol.15 (7), p.747-756 [Peer Reviewed Journal]Elsevier Ltd ;2014 Elsevier Ltd ;Copyright © 2014 Elsevier Ltd. All rights reserved. ;Copyright Elsevier Limited Jun 2014 ;ISSN: 1470-2045 ;EISSN: 1474-5488 ;DOI: 10.1016/S1470-2045(14)70160-3 ;PMID: 24794243 ;CODEN: LANCAOFull text available |
|
13 |
Material Type: Article
|
Assessment of Ki67 in Breast Cancer: Recommendations from the International Ki67 in Breast Cancer Working GroupJNCI : Journal of the National Cancer Institute, 2011-11, Vol.103 (22), p.1656-1664 [Peer Reviewed Journal]The Author 2011. Published by Oxford University Press. 2011 ;Copyright Oxford Publishing Limited(England) Nov 16, 2011 ;ISSN: 0027-8874 ;EISSN: 1460-2105 ;DOI: 10.1093/jnci/djr393 ;PMID: 21960707 ;CODEN: JNCIEQFull text available |
|
14 |
Material Type: Article
|
Comparison of PAM50 Risk of Recurrence Score With Oncotype DX and IHC4 for Predicting Risk of Distant Recurrence After Endocrine TherapyJournal of clinical oncology, 2013-08, Vol.31 (22), p.2783-2790 [Peer Reviewed Journal]2014 INIST-CNRS ;ISSN: 0732-183X ;EISSN: 1527-7755 ;DOI: 10.1200/JCO.2012.46.1558 ;PMID: 23816962Full text available |
|
15 |
Material Type: Article
|
Relationships between Breast Feeding and Breast Cancer Subtypes: Lessons Learned from Studies in Humans and in MiceCancer research (Chicago, Ill.), 2020-11, Vol.80 (22), p.4871-4877 [Peer Reviewed Journal]2020 American Association for Cancer Research. ;ISSN: 0008-5472 ;EISSN: 1538-7445 ;DOI: 10.1158/0008-5472.CAN-20-0077 ;PMID: 32816853Full text available |
|
16 |
Material Type: Article
|
Use of Biomarkers to Guide Decisions on Adjuvant Systemic Therapy for Women With Early-Stage Invasive Breast Cancer: American Society of Clinical Oncology Clinical Practice GuidelineJournal of clinical oncology, 2016-04, Vol.34 (10), p.1134-1150 [Peer Reviewed Journal]2016 by American Society of Clinical Oncology. ;2016 by American Society of Clinical Oncology 2016 American Society of Clinical Oncology ;ISSN: 0732-183X ;EISSN: 1527-7755 ;DOI: 10.1200/JCO.2015.65.2289 ;PMID: 26858339Full text available |
|
17 |
Material Type: Article
|
Prediction of breast cancer risk based on profiling with common genetic variantsJNCI : Journal of the National Cancer Institute, 2015-05, Vol.107 (5), p.1 [Peer Reviewed Journal]The Author 2015. Published by Oxford University Press. ;Copyright Oxford Publishing Limited(England) May 2015 ;The Author 2015. Published by Oxford University Press. 2015 ;ISSN: 0027-8874 ;ISSN: 1460-2105 ;EISSN: 1460-2105 ;DOI: 10.1093/jnci/djv036 ;PMID: 25855707 ;CODEN: JNCIEQFull text available |
|
18 |
Material Type: Article
|
11 years' follow-up of trastuzumab after adjuvant chemotherapy in HER2-positive early breast cancer: final analysis of the HERceptin Adjuvant (HERA) trialThe Lancet (British edition), 2017-03, Vol.389 (10075), p.1195-1205 [Peer Reviewed Journal]Elsevier Ltd ;2017 Elsevier Ltd ;Copyright © 2017 Elsevier Ltd. All rights reserved. ;Copyright Elsevier Limited Mar 25, 2017 ;2017. Elsevier Ltd ;ISSN: 0140-6736 ;EISSN: 1474-547X ;DOI: 10.1016/S0140-6736(16)32616-2 ;PMID: 28215665Full text available |
|
19 |
Material Type: Article
|
Adjuvant Lapatinib and Trastuzumab for Early Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer: Results From the Randomized Phase III Adjuvant Lapatinib and/or Trastuzumab Treatment Optimization TrialJournal of clinical oncology, 2016-04, Vol.34 (10), p.1034-1042 [Peer Reviewed Journal]2015 by American Society of Clinical Oncology. ;2015 by American Society of Clinical Oncology 2015 American Society of Clinical Oncology ;ISSN: 0732-183X ;EISSN: 1527-7755 ;DOI: 10.1200/jco.2015.62.1797 ;PMID: 26598744Full text available |
|
20 |
Material Type: Article
|
West German Study Group Phase III PlanB Trial: First Prospective Outcome Data for the 21-Gene Recurrence Score Assay and Concordance of Prognostic Markers by Central and Local Pathology AssessmentJournal of clinical oncology, 2016-07, Vol.34 (20), p.2341-2349 [Peer Reviewed Journal]2016 by American Society of Clinical Oncology. ;ISSN: 0732-183X ;EISSN: 1527-7755 ;DOI: 10.1200/JCO.2015.63.5383 ;PMID: 26926676Full text available |